All In Biotech

Drug Trial Radar · NCT04827953

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Phase Ib/IIa Study to Evaluate Safety and Efficacy of Treatment With the Hedgehog Inhibitor NLM-001 and Chemotherapy (Gemcitabine and Nab-Paclitaxel) Plus Zalifrelimab as First Line Treatment in Patients With Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

28

Actual

Start

Sep 1, 2021

Primary completion

Apr 2025

Study completion Apr 2025

Sponsor

Lead sponsor
Nelum CorpIndustry
Sponsor type
Industry
Collaborators
Apices Soluciones S.L.; Agenus Inc.
First posted
Apr 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of the signaling pathway of Hedgehog and an immunotherapy drug able of blocking the CTLA-4 receptor.

Conditions

  • Pancreatic Ductal Adenocarcinoma

Interventions

  • GemcitabineDrug

    Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).

  • Nab paclitaxelDrug

    Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).

  • NLM-001Drug

    NLM-001 will be administered three cycles consecutively followed by two rest cycles.

  • ZalifrelimabDrug

    Zalifrelimab administration each 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment efficacy according to responseTime frame: 17 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Marqués del Valdecilla

    Santander, Spain

  • Hospital Clínico Universitario de Santiago

    Santiago de Compostela, A Coruña, Spain

  • Hospital Universitario Virgen De La Victoria

    Málaga, Andalusia, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Aragon, Spain

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Basque Country, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.